Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Insmed, Inc. stock logo
INSM
Insmed
$121.86
-0.8%
$110.69
$90.39
▼
$212.75
$26.96B0.833.75 million shs2.40 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$38.71
+0.3%
$37.32
$19.96
▼
$42.50
$27.98B1.238.73 million shs8.47 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$116.61
+8.5%
$97.27
$74.50
▼
$122.20
$7.45B2.171.83 million shs2.60 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$584.10
-0.6%
$546.33
$455.63
▼
$614.23
$25.04B0.49524,465 shs424,477 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Insmed, Inc. stock logo
INSM
Insmed
-0.83%+1.98%+26.58%-6.74%-38.27%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.26%-6.02%+15.45%+3.50%+88.28%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
+8.49%+2.33%+35.33%+0.76%+15.81%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-0.64%-0.77%+9.56%+10.39%+23.77%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Insmed, Inc. stock logo
INSM
Insmed
$121.86
-0.8%
$110.69
$90.39
▼
$212.75
$26.96B0.833.75 million shs2.40 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$38.71
+0.3%
$37.32
$19.96
▼
$42.50
$27.98B1.238.73 million shs8.47 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$116.61
+8.5%
$97.27
$74.50
▼
$122.20
$7.45B2.171.83 million shs2.60 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$584.10
-0.6%
$546.33
$455.63
▼
$614.23
$25.04B0.49524,465 shs424,477 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Insmed, Inc. stock logo
INSM
Insmed
-0.83%+1.98%+26.58%-6.74%-38.27%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.26%-6.02%+15.45%+3.50%+88.28%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
+8.49%+2.33%+35.33%+0.76%+15.81%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-0.64%-0.77%+9.56%+10.39%+23.77%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Insmed, Inc. stock logo
INSM
Insmed
2.92
Moderate Buy$196.5261.27% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.79
Moderate Buy$46.8220.95% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2.77
Moderate Buy$142.0021.77% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.69
Moderate Buy$676.4015.80% Upside

Current Analyst Ratings Breakdown

Latest RYTM, ROIV, INSM, and UTHR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Reiterated RatingSell (D-)
11/16/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Boost Price TargetBuy$46.00 ➝ $48.00
11/10/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Boost Price TargetBuy$47.00 ➝ $48.00
11/9/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
DowngradeBuy (B-) ➝ Hold (C+)
11/9/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Initiated CoverageBuy$660.00
11/6/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Lower Price TargetOverweight$145.00 ➝ $142.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Boost Price TargetOverweight$700.00 ➝ $703.00
11/5/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Boost Price TargetBuy$143.00 ➝ $147.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Boost Price TargetBuy$675.00 ➝ $700.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Boost Price TargetOutperform$697.00 ➝ $725.00
11/4/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Set Price Target$720.00
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Insmed, Inc. stock logo
INSM
Insmed
$606.42M44.08N/AN/A$3.31 per share36.82
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$8.26M3,395.61N/AN/A$6.34 per share6.11
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$189.76M42.60N/AN/A$1.27 per share91.82
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$3.18B7.82$32.78 per share17.82$147.36 per share3.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$2.82N/A196.55N/A-39.85%-96.38%-32.55%N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.63N/AN/AN/A-838.21%-22.03%-20.55%2/5/2027 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$196.54M-$2.90N/AN/AN/A-69.03%-171.16%-43.00%N/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.33B$26.5022.0418.223.9138.61%19.18%17.07%N/A

Latest RYTM, ROIV, INSM, and UTHR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.01$5.71-$0.30$5.71$781.14 million$832.50 million
11/3/2026Q3 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.7097-$0.61+$0.0997-$0.61$85.56 million$92.13 million
10/29/2026Q3 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.3827-$0.46-$0.0773-$0.46$500.36 million$524.43 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Insmed, Inc. stock logo
INSM
Insmed
0.77
2.86
2.59
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
15.56
15.56
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
2.78
2.57
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
4.61
4.29

Institutional Ownership

CompanyInstitutional Ownership
Insmed, Inc. stock logo
INSM
Insmed
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%

Insider Ownership

CompanyInsider Ownership
Insmed, Inc. stock logo
INSM
Insmed
2.10%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
8.80%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
5.90%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664219.38 million214.77 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
721724.56 million660.80 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
41469.33 million65.24 millionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,40042.59 million38.93 millionOptionable

Recent News About These Companies

United Therapeutics (UTHR) Gets a Hold from Morgan Stanley
SGIOY or UTHR: Which Is the Better Value Stock Right Now?
FY2026 Earnings Forecast for UTHR Issued By HC Wainwright
Analysts Issue Forecasts for UTHR FY2026 Earnings
HC Wainwright Initiates Coverage on United Therapeutics (NASDAQ:UTHR)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Insmed stock logo

Insmed NASDAQ:INSM

$121.86 -1.02 (-0.83%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$120.93 -0.93 (-0.76%)
As of 05:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$38.71 +0.10 (+0.26%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$38.54 -0.16 (-0.43%)
As of 04:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$116.61 +9.13 (+8.49%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$116.14 -0.47 (-0.40%)
As of 05:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$584.10 -3.78 (-0.64%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$584.10 0.00 (0.00%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.